Mycoplasma

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, DNA, MIA, Bacteria, SARS-CoV-2, RSV, Ginkgo Bioworks, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Federal, Vaccine

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • Since its inception in September 2021, the TGS program has demonstrated its ability to serve as an early detection mechanism for new pathogens and fill gaps in global biosurveillance.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • “We are thrilled to have the opportunity to take the TGS program to the next level.

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
O'Hare International Airport, Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, Public, DNA, Bacteria, MIA, SARS-CoV-2, RSV, Ginkgo Bioworks, Federal, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Vaccine

BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • We are honored that CDC continues to trust this consortium to deliver a strategic piece of our biothreat preparedness."
  • "The additional funding of the program allows us to add infrastructure to support new mobile testing centers at Miami International Airport and Chicago O'Hare International Airport.

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Retrieved on: 
Tuesday, February 13, 2024
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Real-time, Conditional sentence, GMP, Quality control, Safety, Thermo Fisher Scientific, Mycoplasma, Organization, PPD, Patient, Patient safety, DSM-IV codes, Cancer, Fine chemical

This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients.

Key Points: 
  • This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients.
  • “There is a growing need globally for biosafety testing, including for new cell and gene therapy targets being discovered and as treatments expand.
  • To ensure their safety, regulatory requirements mandate testing for the presence of pathogens, including mycoplasma.
  • The PPD Laboratory services team’s GMP lab in Middleton offers fully integrated solutions for pharmaceutical product development, including method development and validation, compendial verifications, stability testing, quality control and release testing.

ACROBiosystems launches GM-grade DLL4 Protein to accelerate stem cell manufacturing

Retrieved on: 
Thursday, November 16, 2023
Mycoplasma, IND, Uncertainty, Fibroblast, Growth, B cell, Risk, DLL4, Research, Safety, GMP, Virus, A-DNA, Quality assurance, Vaccine

The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.

Key Points: 
  • The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.
  • The GMP process guarantees that the DLL4 recombinant protein is consistent, contaminant-free, and developed in a controlled production environment for use as a raw material in stem cell culturing.
  • Conventionally, feeder cells such as OP9-DLL4 are employed to secrete DLL4 during the growth and differentiation of stem cells in vitro.
  • As such, these feeder cells are often utilized to stem cell research and develop potential therapies.

GeneProof Announces Expansion of its IVDR-Certified PCR Portfolio

Retrieved on: 
Tuesday, October 3, 2023
Ureaplasma urealyticum, CT, IVDR, Urinary tract infection, Workflow, CP, Infection, Neisseria gonorrhoeae, Chlamydia trachomatis, Real-time, Quality management system, Mycoplasma genitalium, Mycoplasma hominis, NG, Canine vector-borne disease, Diagnosis, PCR, Chlamydia pneumoniae, Medical device, Telecommunications, Ureaplasma, EU, Mycoplasma, Chlamydia

BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.

Key Points: 
  • BRNO, Czech Republic, Oct. 3, 2023 /PRNewswire/ -- GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio.
  • This comes as a testament to the company's dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027.
  • Currently, 27 products are IVDR cleared, with 16 that are Notified Body certified in class C and B.
  • GeneProof was among the first to obtain the EU Certificate for Quality Management System under the new Regulation (EU) 2017/746 IVDR.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”

A pneumonia-causing bug disappeared during the pandemic – but a surge may come this winter

Retrieved on: 
Thursday, July 13, 2023
Infection, Asthma, Urinary tract infection, Kidney, Wheeze, Fever, Tonsillitis, Immunity, Brain, COVID, Diarrhea, Respiratory syncytial virus, Mycoplasma, Sinusitis, Vomiting, Epidemic, School, RSV, Hospital, Swelling, Mycoplasma pneumoniae, Mucositis, Sneeze, Bacteria, Headache, Scarlet fever, Virus, Sore throat, Pneumonia, Mouth, Fatigue, Vaccine, Pharmaceutical industry

There were record numbers of people infected with respiratory syncytial virus (RSV), flu and even strep A.

Key Points: 
  • There were record numbers of people infected with respiratory syncytial virus (RSV), flu and even strep A.
  • But the latest data suggests a surge in infections may be coming this winter.
  • It typically causes a mild chest infection, but it can cause life-threatening illness, such as pneumonia and brain swelling.
  • As with other respiratory infections, M pneumoniae is transmitted when an infected person coughs or sneezes, creating “respiratory droplets”.
  • Crowded places, such as schools and hospitals, are ideal environments for the bug to spread.

Potential resurgence

    • But, contradicting these trends, between April 2021 and March 2022 – when most other respiratory infections had made a comeback- – M pneumoniae infections remained largely absent.
    • Data from 212,207 diagnostic tests collected from 42 sites across 23 countries identified only 214 samples positive for M pneumoniae (0.1% of the samples).
    • The reasons for this lack of resurgence are not fully understood and are probably due to many factors.
    • M pneumoniae infections are known to peak and trough, with epidemics occurring every four to six years as alternative variants circulate.

Global Mycoplasma Testing Market Report 2023: Sector is Expected to Reach $2.26 Billion by 2030 at a CAGR of 13.4% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023
Other Science, Science, Aerosol, Biotechnology, COVID-19, Research, USD, Mycoplasma, Government, ELISA, Investment, Application, Dust, Drug discovery, Growth, FDA, Relaxation, PCR, Fine chemical, Vaccine

The global mycoplasma testing market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.4% over the forecast period.

Key Points: 
  • The global mycoplasma testing market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.4% over the forecast period.
  • The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing.
  • Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.
  • Such factors are likely to drive the market demand for mycoplasma testing solutions.

Agathos Biologics Launches Analytical Services

Retrieved on: 
Wednesday, April 12, 2023
Health, Health Technology, Genetics, Radiology, Research, Science, Biotechnology, QIAGEN, Multimedia, Mycoplasma, Kaay Raav Tumhi, Nested polymerase chain reaction, Biology, Immunohistochemistry, PCR, Microscope, Vaccine, Agatha (given name)

Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers.

Key Points: 
  • Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers.
  • Agathos Biologics uses the latest digital PCR (dPCR) technology, delivering unparalleled sensitivity and precision in nucleic acid quantification.
  • These services represent the first step in our strategy to create breakthrough products and services within a strong ethical and moral framework that benefit everyone.” For more information on high-content imaging and dPCR, visit Agathos Services on our web site.
  • Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy.

Latin America Vitro Diagnostic (IVD) Tests Market Research Report 2023: Focus on Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela - ResearchAndMarkets.com

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Science, Health, Research, Syphilis, Blood, Interleukin, Autoimmunity, Hormone, Molecular biology, Market, Other Nationalities rugby league team, Histology, Toxicology, Torch, NAT, POC, Leukemia, CT, Pregnancy, Gram, Microbiology, Medium (website), DSM-IV codes, Infection, Flow cytometry, FDP, NG, HPV, BNP, Blood culture, EBV, Allergy, COVID-19, MRSA, Fibrinogen, Hepatitis, AIDS, Hemostasis, Anemia, CMV, IVD, APTT, Glycated hemoglobin, Lymphoma, TSH, Fecal occult blood, HIV, Control, PCT, Thrombosis, MTB, Fertility, Coagulation, Cardiology, LATAM, Drug, Vaccine, Medical imaging, Ureaplasma, Sepsis, Mycoplasma, Myoglobin

The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.
  • This market report focuses on the market for reagents and instruments in the most important countries of the region.
  • Brazil and Mexico represent the two largest countries in terms of population, accounting for more than half of LATAM total population.
  • For this reason, these two countries have been the focus of many IVD suppliers in recent years.